Who Paid My Doc
Mark Gajjar
Interventional Cardiology Kyle, TX Medical Doctor
NPI 1942519319 CMS profile 675305
1180 Seton Pkwy Ste 450, Kyle, TX 78640
General payments
$78,476
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$118,589
Through program year 2025, Mark Gajjar of Kyle, TX is reported in the CMS Open Payments database as having received $78,476 across 330 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $118,589 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $49,035 | 100 | |
| 2024 | General | $17,864 | 51 | |
| 2023 | General | $4,208 | 46 | |
| 2022 | General | $1,619 | 19 | |
| 2021 | General | $734 | 17 | |
| 2020 | General | $2,406 | 50 | |
| 2019 | General | $2,609 | 47 |
Beside peers
- Mark Gajjar
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Mark Gajjar were reported at $49,035. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Mark Gajjar | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,609 | $1,097 | $329–$3,048 | $163 |
| 2020 | $2,406 | $473 | $161–$1,480 | $114 |
| 2021 | $734 | $677 | $233–$1,827 | $132 |
| 2022 | $1,619 | $978 | $333–$2,724 | $149 |
| 2023 | $4,208 | $1,136 | $382–$2,986 | $160 |
| 2024 | $17,864 | $1,181 | $395–$3,326 | $164 |
| 2025 | $49,035 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 35 drugsPart D claims
3,449
Drug cost
$467,688
Branded share of claims
20.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 229 | $253,654 | |
| Repatha Sureclick Evolocumab | Brand | 121 | $102,592 | |
| Xarelto Rivaroxaban | Brand | 25 | $36,172 | |
| Entresto Sacubitril/Valsartan | Brand | 27 | $24,942 | |
| Praluent Pen Alirocumab | Brand | 13 | $9,651 | |
| Ezetimibe | Generic | 213 | $6,001 | |
| Jardiance Empagliflozin | Brand | 13 | $5,887 | |
| Atorvastatin Calcium | Generic | 610 | $5,710 | |
| Metoprolol Succinate | Generic | 252 | $3,091 | |
| Rosuvastatin Calcium | Generic | 186 | $2,107 |
The 10 drugs with the highest cost, of 35 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 88 billing codesPaid by Medicare
$203,732
Medicare patients
517
Services billed
2,266
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 62% | |
| Heart failure | 51% | |
| Arthritis | 50% | |
| Atrial fibrillation | 46% | |
| Diabetes | 39% | |
| Chronic kidney disease | 33% | |
| Depression | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, perflutren lipid microspheres, per ml Q9957 | Office | 25 | 53 | $1,630 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
330 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Texas
Juan Granada
Interventional Cardiology · Houston, TX
Vamsi Krishna
Interventional Cardiology · Kyle, TX
Jeffrey Carr
Interventional Cardiology · Tyler, TX
John Isaac
Interventional Cardiology · Houston, TX
Robert Chilton
Interventional Cardiology · San Antonio, TX
Sameh Sayfo
Interventional Cardiology · Plano, TX
Related records
Interventional Cardiology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.